About us – a timeline

Xspray Pharma has developed today’s technology and refined the business model for a long time.

2023
Xspray Pharma strengthened its commercial organization ahead of the launch of Dasynoc® and signed a partnership agreement with EVERSANA ahead of the launch and commercialization of Dasynoc® in the US. The company reached a settlement with Bristol Myers Squibb that clears all pending claims on Dasynoc® and paves the way for Xspray Pharma to launch Dasynoc® in the beginning of September 2024, pending final FDA approval. Xspray Pharma continued its work on two additional publicized product candidates derived from the company’s HyNap technology platform: XS003 nilotinib and XS008 axitinib. Bioavailability comparable to Tasigna® was achieved with XS003 nilotinib.

2022
In January 2022, the FDA announced that they will commence a full review of the application for market approval of XS004. Bristol Myers Squibb filed a lawsuit against Xspray Pharma for patent infringement in February 2022. The FDA granted XS004 Orphan Drug Status during the year for treatment of both chronic myeloid leukemia and acute lymphatic leukemia.

2021
Bioequivalence is achieved in pivotal bioequivalence study with XS004 dasatinib compared with the reference product Sprycel^®. The result demonstrate that the dose strength can be reduced by 30% but still yield the same uptake in the body as the reference product. The application for US market approval of the first product candidate XS004 dasatinib is submitted to the Food and Drug Administration (FDA) under the 505(b)(2) NDA procedure, which is the registration path that applies to improved drugs.
The company decides to focus entirely on improved PKIs, since the value of generics in the calculating models has gradually decreased, while the value of improved drugs has instead increased.

2020
The essential supply chain for the commercial production of XS004 dasatinib from supply of the active substance to the final product is secured. Study demonstrates that solubility and absorbtion of XS004 dasatinib is not dependent on the gastric acidity (pH level), and is not affected during proton pump inhibitor treatment, like Omeprazol. Preparations for submission of Xspray Pharma´s first application for market approval to the FDA completed. Development work carried out for the next product candidate HyNap-Nilo (nilotinib). The FDA’s Orphan Drug Designation (ODD) is granted to Xspray Pharma for nilotinib oral formulation intended for the treatment of chronic myeloid leukemia. Planning for a manufacturing facility in Malta started.

2017 – 2019
Start of the scale up of the HyNap technology begins. Development of a new GMP-classified production facility with the Italian partner NerPharMa. First GMP batch of HyNap-Dasa amorphous material manufactured on a commercial scale. Development of final tablet of XS004 dasatinib and manufacture of GMP batches on a commercial scale of final tablets at a US supplier.

2011 – 2016
The Company’s HyNap technology is developed with a focus on protein kinase inhibitors (PKIs). Positive results are shown from three clinical studies of an improved and generic version of XS004 dasatinib, respectively. The FDA confirms that the Company’s clinical trials with XS004 dasatinib can be performed in healthy subjects and that no studies on cancer patients are required for approval.

2003 – 2010
Xspray Pharma was founded, based on the development of a new nozzle that enables a unique upscaling of particle technology. Scale-up of technology proven in a new pilot plant ten times larger than the lab system.